Pure Global
NCT06082765

Cervical Cancer Screening With NGS-HPV Technology Based on Menstrual Blood

Zhongnan Hospital·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cervical Cancer
Study type
Observational
Sponsor & location
Primary sponsor
Zhongnan Hospital
Location
Wuhan, China
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2021
End date
Mar 31, 2028
Enrollment
10000 participants
Primary outcome

HPV detection in menstrual blood

Summary

Our study is conducted to recruit cervical cancer screening patients to evaluate the
 application value of using high-throughput sequencing technology to detect HPV in menstrual
 blood for cervical cancer screening.

ICD-10 classifications
Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06082765
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06082765 through Pure Global AI's free database. This phase not specified trial is sponsored by Zhongnan Hospital and is currently Recruiting. The study focuses on Cervical Cancer. Target enrollment is 10000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.